InDex signs license agreement with Viatris Japan to develop and commercialize cobitolimod in Japan.
”Their experience and presence in the local gastrointestinal segment will ensure that we maximize our sales potential and bring the benefits of this innovative therapy to patients”, says Jenny Sundqvist, CEO of InDex
In focus interview with
CEO Jenny Sundqvist
@Redeye Growth Day
10.55 am CET on 1 June 2023
Watch InDex Pharmaceuticals
Business Update
Our mission is to significantly improve
the lives of patients suffering from
immunological disorders by providing
effective and safe drugs for diseases
with high unmet medical needs.
InDex Pharmaceuticals is developing cobitolimod for the treatment of moderate to severe ulcerative colitis
-
InDex Pharmaceuticals’ investor call at 15:00 CET on June 1
May 31, 2023 Non Regulatory
-
InDex Pharmaceuticals announces license agreement with Viatris Japan to develop and commercialize cobitolimod in Japan
May 31, 2023 Regulatory
InDex Pharmaceuticals published the interim report for Q1 2023 on May 24, 2023.
-
Interim Report Q2 2023
-
Interim Report Q3 2023
-
Year-end Report 2023
Our phase III program CONCLUDE
Have a look at InDex’s corporate presentation
InDex Pharmaceuticals is developing cobitolimod for treatment of moderate to severe left-sided ulcerative colitis
Proud partner of:
